Spots Global Cancer Trial Database for futibatinib
Every month we try and update this database with for futibatinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer | NCT04965818 | Advanced or Met... Non-Small Cell ... KRAS Gene Mutat... | Futibatinib and... | 18 Years - | Taiho Oncology, Inc. | |
| Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements | NCT04507503 | Advanced Cholan... | TAS-120 | 18 Years - | Taiho Oncology, Inc. | |
| Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy | NCT06263153 | Bladder Urothel... Muscle Invasive... Stage II Bladde... Stage IIIA Blad... | Biospecimen Col... Computed Tomogr... Durvalumab Futibatinib Magnetic Resona... Radical Cystect... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma | NCT04601857 | Advanced and Me... | futibatinib and... | 18 Years - | Taiho Oncology, Inc. | |
| Personalized Medicine for Advanced Biliary Cancer Patients | NCT05615818 | Biliary Tract N... | Futibatinib Ivosidenib Zanidatamab Trastuzumab Neratinib Encorafenib Binimetinib Niraparib Cisplatin Gemcitabine | 18 Years - | UNICANCER | |
| A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma | NCT05036681 | Metastatic Canc... Endometrium Can... Endometrial Car... | Futibatinib Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | NCT05945823 | Locally Advance... Esophageal Aden... Esophageal Squa... Siewert Type 1 ... Pancreatic Canc... | Futibatinib Pembrolizumab Cisplatin 5-FU Oxaliplatin Leucovorin Levoleucovorin Irinotecan | 18 Years - | Taiho Oncology, Inc. | |
| A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma | NCT05036681 | Metastatic Canc... Endometrium Can... Endometrial Car... | Futibatinib Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) | NCT03767075 | Advanced Solid ... | Atezolizumab Futibatinib Amivantamab | 18 Years - | Vall d'Hebron Institute of Oncology | |
| A Study of TAS-120 in Patients With Metastatic Breast Cancer | NCT04024436 | Metastatic Brea... FGFR 1 High Amp... FGFR2 Amplifica... | Futibatinib Futibatinib plu... | 18 Years - | Taiho Oncology, Inc. | |
| A Study of TAS-120 in Patients With Metastatic Breast Cancer | NCT04024436 | Metastatic Brea... FGFR 1 High Amp... FGFR2 Amplifica... | Futibatinib Futibatinib plu... | 18 Years - | Taiho Oncology, Inc. | |
| Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer | NCT04965818 | Advanced or Met... Non-Small Cell ... KRAS Gene Mutat... | Futibatinib and... | 18 Years - | Taiho Oncology, Inc. | |
| A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma | NCT05036681 | Metastatic Canc... Endometrium Can... Endometrial Car... | Futibatinib Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Futibatinib in Patients With Specific FGFR Aberrations | NCT04189445 | Advanced or Met... Advanced or Met... Myeloid or Lymp... | Futibatinib | 18 Years - | Taiho Oncology, Inc. | |
| A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) | NCT03767075 | Advanced Solid ... | Atezolizumab Futibatinib Amivantamab | 18 Years - | Vall d'Hebron Institute of Oncology | |
| Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements | NCT04507503 | Advanced Cholan... | TAS-120 | 18 Years - | Taiho Oncology, Inc. | |
| Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma | NCT04601857 | Advanced and Me... | futibatinib and... | 18 Years - | Taiho Oncology, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
